Abstract
Background and Aims: Haematological and immunological adverse effects and significant injection-site adverse events (AEs) have been reported with some early generation anti-sense oligonucleotide (RNA-based) therapies, which required frequent dosing and had non-specific organ uptake. Inclisiran is a novel small interfering RNA (siRNA) therapy with twice-yearly dosing, and conjugated with trivalent N-Acetylgalactosamine (GalNAc) enabling targeted hepatic delivery. Here, we assessed the effects of inclisiran on haematological and immunological biomarkers.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
